Long term response to low-dose Rituximab in bullous pemphigoid: a case series

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• Rituximab is used in a number of autoimmune diseases at 375 mg/m² QW over 4 weeks for lymphoma, and 1000 mg 2 weeks apart for RA.
• Lower doses may be an option in some diseases such as pemphigus
• This retrospective analysis of 6 patients with BP evaluated the efficacy of low-dose rituximab (500 mg 2 weeks apart) in the long term.
• Over mean follow-up of 97 weeks, 83% sustained or improved their response over time.
• This pilot suggests response to two infusions is maintained over time; this may be an option especially for older patients where full-dose may cause unacceptable toxicity.